SecBot SecBot
8-K ·Filed Aug 13, 2026

KOD

Kodiak Sciences Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001193125-26-349107
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock's near-term catalyst is the DAYBREAK Phase 3 readout in September 2026. Monitor cash runway closely, at the current burn rate, a dilutive equity offering is likely needed before mid-2027 to fund operations through the PEAK and PINNACLE readouts.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

KOD drug pipeline →

KSI-101

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
Next catalyst
None dated

What to watchThe December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.

Price Chart

Loading chart...

Executive Summary

Kodiak Sciences reported Q2 2026 financial results with a net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, driven by increased R&D spending on late-stage trials. The pre-revenue biotech remains on track for three pivotal Phase 3 readouts by year-end: DAYBREAK (wet AMD) in September 2026 and PEAK (MESI) in December 2026. Cash burn accelerated to $84M in H1 2026, leaving $125.9M in cash, sufficient into 2027 but raising the likelihood of a dilutive financing before commercialization.

Key Financial Metrics

EPS
−$1.05
est −$0.97 · -8.3%
Rating
in line

Key Facts

  • Net loss for Q2 2026 was $65.6M ($1.05/share) vs $54.3M ($1.03/share) in Q2 2025.
  • Cash and cash equivalents fell to $125.9M at June 30, 2026, from $209.9M at December 31, 2025.
  • R&D expenses rose to $56.1M in Q2 2026 from $42.8M in Q2 2025, driven by PEAK/PINNACLE and manufacturing activities.
  • Enrollment completed for the first 300-patient cohort of the Phase 3 PEAK study (KSI-101 in MESI); topline data expected December 2026.
  • Phase 3 DAYBREAK study (Zenkuda and KSI-501 in wet AMD) topline data expected September 2026.
  • First patients enrolled in the Phase 3 ALTO study of KSI-501 in diabetic macular edema (DME).
  • BLA preparation activities for Zenkuda continue.
  • Working capital decreased to $78.6M from $169.3M at year-end 2025.
  • Total stockholders' equity fell to $61.1M from $157.4M at December 31, 2025.

Financial Impact

Net loss widened by $11.3M YoY to $65.6M in Q2 2026; cash burn of ~$84M in H1 2026

net losscash positionR&D expensesworking capital

Risk Factors

  • Cash burn rate is accelerating, with $84M consumed in H1 2026, potentially requiring dilutive financing before commercialization.
  • Phase 3 DAYBREAK and PEAK readouts are binary events; failure to meet primary endpoints would significantly impair the pipeline's value.
  • No revenue or approved products; the company is entirely dependent on clinical trial success and regulatory approvals.
  • Accumulated deficit has grown to $1.68 billion, with no path to profitability in the near term.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-349107
Document: kod-20260813.htm0001193125-26-349107
Document: 0001193125-26-349107-index-headers.html0001193125-26-349107
Document: 0001193125-26-349107-index.html0001193125-26-349107
Document: 0001193125-26-349107.txt0001193125-26-349107
8-K Data (Synthetic)0001193125-26-349107

Track record

13 reports on KOD

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $100.73 +4.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $100.73 +8.01% settles Dec 15
  3. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $100.73 −9.41% settles Dec 14
  4. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $100.73 −5.95% settles Dec 8
  5. Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $100.73 −14.83% settles Nov 18
  6. Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
  7. Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
  8. Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $100.73 +12.02% ▼ −0.36% −0.32% vs SPY
  9. Aug 13, 202613w ago 8-K Neutral 4/10 Viewing No price data
  10. Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $100.73 +143.60% ▼ −19.85% −17.86% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (14h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026